SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
The company plans to submit the vaccine for regulatory review
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
Subscribe To Our Newsletter & Stay Updated
